Stevanato Group

Articles

Stevanato Group’s integrated offering addressing mAbs challenges includes Aidaptus®, a 2-step single-use auto-injector accommodating 1mL and 2.25mL PFSs in the same base device, supporting a range of drug viscosities for reliable delivery.


Delivering added value in auto-injectors through strategic supply chain partnership

Don't miss this webinar delving into: 
- How to streamline the selection of the primary container and delivery device
- How to overcome silicone challenges in PFSs
- How to enhance the delivery of highly viscous drug formulation


Innovative Solutions in Pre-Filled Syringes for Biologics and Ophthalmic Applications

The release of subvisible silicone particles and the risks associated with silicone oil droplets are major factors that can compromise the safety and efficacy of sensitive drugs. Download this white paper and discover how Stevanato Group's innovative syringe platform answers this challenge.

Solving the Silicone Challenge in Pre-fillable Syringes

For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible. Read this white paper and discover how Stevanato Group can support you from start to finish.

Container selection for a highly sensitive drug product: a success story

Commercializing a drug-device combination product is a complex challenge to handle alone. Learn how Stevanato Group’s Technology Excellence Centers can provide guidance and execution through the various steps of a Validation Master Plan. 

Design testing strategies to develop a drug-device combination product

Innovative drug delivery solutions are evolving due to advances in biotechnology and the demand for biologics, focusing on user-friendly devices that improve patient compliance and support high-viscosity, large-volume treatments and various therapies.

Driving Innovation in Drug Delivery: Stevanato Group’s Integrated Solutions for Evolving Patient Needs

At DCAT 2025, Riccardo Butta, President, Drug Delivery Systems & In-Vitro Diagnostic Business Unit at Stevanato Group, discussed key innovations and strategies the company is employing to address the evolving landscape of drug delivery and containment. One of the primary topics highlighted was how advancements in biotechnology and the growing demand for biologics are driving the need for integrated solutions in drug delivery. Butta emphasized the importance of user-friendly devices that enhance patient compliance, especially in the context of the rise in home-based treatments and therapies involving high-viscosity and large-volume drugs. Additionally, he outlined how the company’s comprehensive solutions, including its platforms like Alina®, Aidaptus®, and Vertiva®, are designed to support a wide range of therapies while offering robust manufacturing capabilities.

Understand how advancements in biotechnology and the increasing demand for biologics are shaping the future of drug containment and delivery solutions.

Explore the growing need for user-friendly devices that improve patient compliance, especially for home-based treatments and therapies with complex characteristics.

Learn about comprehensive solutions, including contract manufacturing and platforms, that support a wide range of therapies and drive innovation in the drug delivery sector.